Home › Sistema ng Imunidad at mga Karamdaman › New York › New York City
Pag-aaral pangklinika para sa Sistema ng Imunidad at mga Karamdaman sa New York City, NY
Isang pag-aaral para sa Sistema ng Imunidad at mga Karamdaman ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa New York City. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Nagre-recruitPhase 3
- Memorial Sloan Kettering Cancer Center, New York
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Nagre-recruitPhase 3
- Memorial Sloan Kettering Cancer Center, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Nagre-recruitPhase 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Abatacept for the Treatment of Giant Cell Arteritis
Nagre-recruitPhase 3
- Hospital for Special Surgery, New York
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Nagre-recruitPhase 3
- Icahn School of Medicine at Mount Sinai, New York
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Nagre-recruitPhase 2
- Inmagene Site 21, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Nagre-recruitPhase 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
Nagre-recruitPhase 2
- Columbia University Irving Medical Center, New York
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Nagre-recruitPhase 1/2
- Columbia University, New York
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Nagre-recruitPhase 1/2
- Mt Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Biologics And Clinical Immunology Cohort at Sinai
Nagre-recruitObservasyonal na pag-aaral
- Mount Sinai, New York
Pag-aaral para sa Sistema ng Imunidad at mga Karamdaman sa ibang lungsod
- Washington, DC13 pag-aaral
- Philadelphia, PA10 pag-aaral
- Boston, MA10 pag-aaral
- Portland, OR9 pag-aaral
- Atlanta, GA9 pag-aaral
- Houston, TX9 pag-aaral
- Cleveland, OH8 pag-aaral
- Los Angeles, CA8 pag-aaral
- Chicago, IL8 pag-aaral
- Milwaukee, WI6 pag-aaral
- Seattle, WA6 pag-aaral
- Cedar Rapids, IA6 pag-aaral
Iba pang pag-aaral sa New York City
- Kanser sa Suso136 pag-aaral
- Non-Small Cell Lung Cancer121 pag-aaral
- Kanser (lahat ng uri)109 pag-aaral
- Kanser sa Prostate103 pag-aaral
- Metastatic Cancer93 pag-aaral
- Colorectal Cancer78 pag-aaral
- Kanser sa Ovary69 pag-aaral
- Kanser sa Baga60 pag-aaral
- Multiple Myeloma60 pag-aaral
- Kanser sa Pancreas60 pag-aaral
- Kanser ng Endometrium52 pag-aaral
- Acute Myeloid Leukemia51 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.